Randomized phase III GnG study on two schedules of gemtuzumab ozogamicin as adjunct to intensive induction therapy and double-blinded intensive postremission therapy with or without glasdegib in patients with newly diagnosed acute myeloid leukemia

• Sonia Jaramillo,
• Johannes Krisam,
• Lucian Le Cornet,
• Markus Kratzmann,
• Lukas Baumann,
• Olga Eissymont,
• Martina Crysandt,
• Martin Görner,
• Sabine Kayser,
• Stefan Krause,
• Christoph Schliemann,
• Tobias Gaska,
• Martin Kaufmann,
• Jens Chemnitz,
• Markus Schaich,
• Alexander Hoellein,
• Uwe Platzbecker,
• Meinhard Kieser,
• Carsten Müller-Tidow,
• Richard F. Schlenk

Affiliations

Sonia Jaramillo

Department of Internal Medicine V, Heidelberg University Hospital

Johannes Krisam

Institute of Medical Biometry, University of Heidelberg

Lucian Le Cornet

NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center

Markus Kratzmann

NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center

Lukas Baumann

Institute of Medical Biometry, University of Heidelberg

Olga Eissymont

Institute of Medical Biometry, University of Heidelberg

Martina Crysandt

Department of Medicine IV, Aachen University Hospital, Aachen

Martin Görner

Department of Hematology, Oncology and Palliative Medicine, Community Hospital Bielefeld

Sabine Kayser

NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center, Germany; Institute of Transfusion Medicine and Immunology, Medical Faculty Mannheim, Heidelberg University; Department of Medicine I – Hematology and Cell Therapy, University Hospital Leipzig

Stefan Krause

Department of Medicine V, Erlangen University Hospital

Christoph Schliemann

Department of Medicine A, Münster University Hospital

Tobias Gaska

Department of Hematology and Oncology, St. Josef Brothers’ Hospital Paderborn

Martin Kaufmann

Department of Hematology, Oncology and Palliative Medicine, Robert-Bosch Hospital Stuttgart

Jens Chemnitz

Department of Internal Medicine, Hematology, Oncology and Palliative Medicine, Prot. Monastery Hospital St. Jakob Koblenz

Markus Schaich

Department of Hematology, Oncology and Palliative Medicine, Winnenden Hospital, Winnenden

Alexander Hoellein

Department of Internal Medicine III - Hematology and Oncology, Red Cross Hospital Munich, Munich

Uwe Platzbecker

Department of Medicine I – Hematology and Cell Therapy, University Hospital Leipzig

Meinhard Kieser

Institute of Medical Biometry, University of Heidelberg

Carsten Müller-Tidow

Department of Internal Medicine V, Heidelberg University Hospital

Richard F. Schlenk

Department of Internal Medicine V, Heidelberg University Hospital, Germany; NCT-Trial Center, National Center of Tumor Diseases, Heidelberg University Hospital and German Cancer Research Center